Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

Also known as a polymyxin B haemoperfusion (PMX), Toraymyxin is a haemoperfusion device that removes endotoxin, a toxic ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Radella Pharmaceuticals has reported topline outcomes from a Phase Ia trial that assessed an investigational therapy for ...

Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The former health minister predicted a bright future for UK trials and outlined steps to ensure clinical research thrives.

Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM' pipeline disease-modifying therapies for ...

Research Grid has raised a $6.5m seed funding round led by Fuel Ventures, to improve the success rate of clinical trials.

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with solid ...

The community screening programme charts an effective, affordable framework for TB control in the Canadian province of ...

Oak Hill Bio and Chiesi have enrolled the first European patient in a Phase IIb study for OHB-607, to prevent BPD in infants.